TABLE 1.
Sequence analysis of H3N2 variants selected in vivo and in vitro
| Patient | In vivo
|
In vitrod
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDCK cells
|
SIAT1-MDCK cells
|
|||||||||||||||||||
| Virus from patient before treatment
|
Virus from patient after amantadine treatment
|
Without amantadine
|
With amantadine
|
Without amantadine
|
With amantadine
|
|||||||||||||||
| 3rd-passage virus
|
10th-passage virus
|
3rd-passage virus
|
10th-passage virus
|
3rd-passage virus
|
10th-passage virus
|
3rd-passage virus
|
10th-passage virus
|
|||||||||||||
| M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | M2 | HA | |
| 1 | NDa | ND | S31N | —b | ND | R229G | ND | R229G | ND | P221L | S31N | S137Y, P221L | ND | — | ND | — | ND | — | S31N | — |
| 2 | ND | ND | S31N | — | ND | R229I | ND | R229I | ND | R229I | S31N | R229I | ND | — | ND | — | ND | — | S31N | — |
| 3 | ND | ND | A30T | — | ND | R220G | ND | R220G | ND | R229K, I236V | S31N | R229K, I236V | ND | — | ND | — | ND | — | L26F | — |
| 4 | ND | ND | V27A | — | ND | R229K | ND | R229K | ND | R229K | V27A | R50G, V106A, D144N, G186S, S199P, R229I, S247C, P273S, | ND | — | ND | — | ND | — | A30V | — |
| 5 | ND | ND | S31N | — | ND | V226I | ND | V226I | ND | V226I | S31N | V226I | ND | — | ND | — | ND | — | V27G | — |
| 6 | ND | ND | S31N | — | ND | — | ND | R83K, H183L, A147Tc | ND | — | V27A | R83K, H183L, A147Tc | ND | — | ND | R83K, A147Tc | ND | — | S31N | R83K, A147Tc |
| 7 | ND | ND | S31N | — | ND | H183L | A30T | H156N, T147A,c G150Ec | ND | H183L | S31N | H156N, T147A,c G150Ec | ND | — | ND | — | ND | — | A30V | H156N, T147Ac G150Ec |
a
ND, mutation not detected.
b
—, No mutation was detected compared to the virus collected from the patient at the first clinic visit.
c
Substitutions which are located within the HA2 subunit.
d
Viruses used in the in vitro study were those obtained from patients before amantadine treatment.